Signature Wealth Management Group Buys 413 Shares of Johnson & Johnson $JNJ

Signature Wealth Management Group increased its stake in Johnson & Johnson (NYSE:JNJ) by 1.4% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 29,039 shares of the company’s stock after purchasing an additional 413 shares during the quarter. Johnson & Johnson makes up approximately 1.8% of Signature Wealth Management Group’s portfolio, making the stock its 17th biggest holding. Signature Wealth Management Group’s holdings in Johnson & Johnson were worth $4,436,000 at the end of the most recent reporting period.

A number of other hedge funds also recently modified their holdings of JNJ. GFG Capital LLC bought a new stake in Johnson & Johnson during the 2nd quarter valued at $35,000. Stone House Investment Management LLC bought a new stake in Johnson & Johnson during the 1st quarter valued at $47,000. 1248 Management LLC bought a new stake in Johnson & Johnson during the 1st quarter valued at $48,000. von Borstel & Associates Inc. bought a new stake in Johnson & Johnson during the 1st quarter valued at $49,000. Finally, Harvest Fund Management Co. Ltd bought a new stake in Johnson & Johnson during the 1st quarter valued at $52,000. Institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Stock Down 1.1%

Shares of NYSE:JNJ opened at $190.38 on Monday. Johnson & Johnson has a 52-week low of $140.68 and a 52-week high of $194.48. The firm has a fifty day moving average of $182.26 and a 200 day moving average of $166.37. The firm has a market capitalization of $458.69 billion, a PE ratio of 18.38, a price-to-earnings-growth ratio of 2.24 and a beta of 0.40. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.80 and a current ratio of 1.07.

Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Wednesday, August 30th. The company reported $2.26 earnings per share (EPS) for the quarter. Johnson & Johnson had a net margin of 27.26% and a return on equity of 32.73%. The company had revenue of $24.02 billion during the quarter. As a group, research analysts anticipate that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 9th. Investors of record on Tuesday, November 25th will be given a $1.30 dividend. The ex-dividend date is Tuesday, November 25th. This represents a $5.20 annualized dividend and a yield of 2.7%. Johnson & Johnson’s payout ratio is 50.19%.

Insider Transactions at Johnson & Johnson

In related news, EVP Jennifer L. Taubert sold 56,471 shares of the company’s stock in a transaction on Thursday, September 4th. The shares were sold at an average price of $177.81, for a total value of $10,041,108.51. Following the completion of the transaction, the executive vice president directly owned 178,013 shares in the company, valued at approximately $31,652,491.53. The trade was a 24.08% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 0.16% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on JNJ shares. Daiwa Capital Markets raised shares of Johnson & Johnson from a “neutral” rating to an “outperform” rating and set a $203.00 target price on the stock in a report on Monday, October 20th. Daiwa America upgraded shares of Johnson & Johnson from a “hold” rating to a “strong-buy” rating in a research report on Monday, October 20th. Wells Fargo & Company set a $212.00 price target on shares of Johnson & Johnson and gave the company an “overweight” rating in a research report on Friday, October 3rd. Wall Street Zen upgraded shares of Johnson & Johnson from a “hold” rating to a “buy” rating in a research report on Saturday, September 13th. Finally, Citigroup boosted their price target on shares of Johnson & Johnson from $213.00 to $215.00 and gave the company a “buy” rating in a research report on Wednesday, October 15th. Three research analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and nine have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, Johnson & Johnson currently has a consensus rating of “Moderate Buy” and an average target price of $199.05.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.